

1-5 (Canceled)

6. (Currently amended) A pharmaceutical composition for treating or ameliorating type 1 diabetes comprising a hormonally inactive insulin analogue in an amount effective for said treating or ameliorating, wherein said analogue is selected from the group consisting of desA1 human insulin, des(A1-A2) human insulin, des(A1-A3) human insulin, desA21 human insulin, des(B1-B5) human insulin, des(B1-B6) human insulin, des(B24-B30) human insulin, des(B25-B30) human insulin, Gly<sup>A2</sup> human insulin, Ala<sup>A2</sup> human insulin, Nle<sup>A2</sup> human insulin, Thr<sup>A2</sup> human insulin, Pro<sup>A2</sup> human insulin, D-allo Ile<sup>A2</sup> human insulin, Nva<sup>A3</sup> human insulin, Nle<sup>A3</sup> human insulin, Leu<sup>A3</sup> human insulin, Val<sup>A2</sup>, Ile<sup>A3</sup> human insulin, Abu<sup>A2</sup>, Abu<sup>A3</sup> human insulin, Gly<sup>A2</sup>, Gly<sup>A3</sup> human insulin, D-Cys<sup>A6</sup> human insulin, D-Cys<sup>A6</sup>, D-Cys<sup>A11</sup> human insulin, Ser<sup>A6</sup>, Ser<sup>A11</sup>, des(A8-A10) human insulin, D-Cys<sup>A7</sup> human insulin, D-Cys<sup>A11</sup> human insulin, Leu<sup>A19</sup> human insulin, Gly<sup>B6</sup> human insulin, Glu<sup>B12</sup> human insulin, Asn<sup>B12</sup> human insulin, Phe<sup>B12</sup> human insulin, D-Ala<sup>B12</sup> human insulin, and Asp<sup>B25</sup> human insulin.

7. (Canceled)

8. (Currently amended) The pharmaceutical composition of claim 6, wherein the ~~*in-vitro*~~ activity of the insulin analogue in an *in vitro* fat cell or receptor binding assay is less than 7% of the activity of human insulin.

9. (Original) The pharmaceutical composition of claim 6, wherein the insulin analogue is Asp<sup>B25</sup> human insulin.

10. (Canceled)

11. (Withdrawn) The pharmaceutical composition of claim 6, wherein the insulin analogue is in the form of hexameric complexes in a solution.